19 hours Ago By Defense World Staff
Charles Schwab Investment Management Inc. boosted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 9.
5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,931,114 shares of the company’s stock after purchasing an additional 167,997 shares during the quarter. Charles Schwab Investment Management Inc.
owned about 1.15% of Revolution Medicines worth $84,467,000 at the end of the most recent quarter. A number of other large investors have also recently added to or reduced their stakes in RVMD.
Lord Abbett & CO. LLC bought a new stake in Revolution Medicines during the third quarter worth approximately $83,082,000. Janus Henderson Group PLC boosted its position in Revolution Medicines by 32.
3% during the third quarter. Janus Henderson Group PLC now owns 6,137,244 shares of the company’s stock worth $278,280,000 after purchasing an additional 1,497,026 shares during the period. Fred Alger Management LLC boosted its position in Revolution Medicines by 2,384.
3% during the third quarter. Fred Alger Management LLC now owns 540,673 shares of the company’s stock worth $24,520,000 after purchasing an additional 518,909 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Revolution Medicines by 8.
7% during the third quarter. Geode Capital Management LLC now owns 3,627,025 shares of the company’s stock worth $164,517,000 after buying an additional 291,369 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Revolution Medicines by 4.
4% during the third quarter. FMR LLC now owns 5,875,893 shares of the company’s stock worth $266,472,000 after buying an additional 250,037 shares during the last quarter. Institutional investors own 94.
34% of the company’s stock. Revolution Medicines Price PerformanceRevolution Medicines stock opened at $36.82 on Tuesday.
The stock has a fifty day moving average price of $41.46 and a two-hundred day moving average price of $46.00.
Revolution Medicines, Inc. has a 52-week low of $29.55 and a 52-week high of $62.
40. The firm has a market capitalization of $6.85 billion, a P/E ratio of -10.
26 and a beta of 1.46. Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings data on Wednesday, February 26th.
The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.
11). On average, equities research analysts predict that Revolution Medicines, Inc. will post -3.
49 EPS for the current fiscal year. Analyst Upgrades and DowngradesA number of brokerages have recently commented on RVMD. UBS Group upped their price target on Revolution Medicines from $65.
00 to $71.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Guggenheim upped their price target on Revolution Medicines from $82.
00 to $87.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Wedbush reiterated an “outperform” rating and set a $67.
00 price target on shares of Revolution Medicines in a report on Thursday, February 27th. HC Wainwright upped their price target on Revolution Medicines from $72.00 to $73.
00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Finally, Needham & Company LLC cut their price target on Revolution Medicines from $60.00 to $59.
00 and set a “buy” rating for the company in a report on Thursday, February 27th. Twelve research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $66.
31.Get Our Latest Stock Analysis on Revolution MedicinesInsiders Place Their BetsIn other news, CFO Jack Anders sold 2,635 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $45.
40, for a total transaction of $119,629.00. Following the sale, the chief financial officer now owns 96,470 shares in the company, valued at approximately $4,379,738.
This represents a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Also, insider Mark A. Goldsmith sold 11,714 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $45.
40, for a total value of $531,815.60. Following the sale, the insider now owns 325,056 shares in the company, valued at $14,757,542.
40. The trade was a 3.48 % decrease in their position.
The disclosure for this sale can be found here. Insiders sold 18,678 shares of company stock worth $847,981 over the last three months. 8.
00% of the stock is currently owned by corporate insiders. About Revolution Medicines (Free Report)Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Featured ArticlesFive stocks we like better than Revolution MedicinesWhat is the Dogs of the Dow Strategy? Overview and ExamplesHow to Protect Your Portfolio When Inflation Is RisingTechnology Stocks Explained: Here’s What to Know About Tech3 Tech Stocks Defying Sector Weakness and Thriving in 2025Consumer Discretionary Stocks ExplainedDespite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors.
